Innovent's Mazdutide 9 mg Shows Promising Efficacy in Weight Management for Chinese Adults

Innovent Biologics, Inc. recently announced significant results from its Phase 3 clinical trial concerning Mazdutide 9 mg, a dual glucagon/glucagon-like peptide-1 receptor agonist designed for weight management. This trial, named GLORY-2, involved 462 Chinese adults diagnosed with obesity, effectively showcasing the drug's potential benefits in combating weight issues prevalent in the population.

Overview of the Trial

The GLORY-2 trial was primarily structured to evaluate the efficacy of Mazdutide 9 mg combined with lifestyle interventions compared to a placebo. Participants, averaging a body mass index (BMI) of 34.3 kg/m², were observed over a 60-week double-blind treatment period. The results were promising, indicating a mean weight reduction of 18.55% for those administered the Mazdutide compared to just 3.02% for the placebo group. An impressive 44% of the Mazdutide group achieved a weight loss of 20% or more, a feat only met by 2.6% of the placebo recipients.

Key Findings

Those without Type 2 diabetes also saw substantial results, with the Mazdutide group experiencing a mean weight reduction of 20.08% at the end of the trial. In addition to overall weight loss, the trial assessed key secondary endpoints including waist circumference reduction and various cardiometabolic improvements such as lowering blood pressure and triglyceride levels. Notably, the reduction of liver fat content in participants with baseline liver fat higher than 10% was remarkable, decreasing by 71.9% in the Mazdutide group compared to only 5.1% in the placebo cohort.

Professor Linong Ji, the leading principal investigator, emphasized the importance of public awareness regarding long-term treatment and management of obesity, given the high prevalence of this condition in China. He noted that the results highlight the necessity for modern pharmacological treatments for managing obesity effectively, being particularly crucial for individuals bearing a significant cardiometabolic burden.

Dr. Lei Qian, Innovent's Chief RD Officer, pointed out that Mazdutide 9 mg stands out as the only GLP-1 receptor agonist leading to over 20% weight loss in obese individuals without Type 2 diabetes after just one year of treatment. This breakthrough paves the way for an alternative to metabolic surgery, providing a robust medical foundation for weight management strategies tailored to the needs of the Chinese populace.

Future Directions

Innovent's plans include submitting a new drug application (NDA) for Mazdutide 9 mg to the Center for Drug Evaluation of China's National Medical Products Administration in the near future. Additionally, the company is exploring further therapeutic applications for Mazdutide, including studies for adolescents with obesity and heart failure patients alongside various other metabolic disorders.

The innovative treatment has already gained significant recognition, being featured in prestigious journals and listed among the most anticipated drug launches of 2025 by FIERCE Pharma. With clinical studies validating its safety and efficacy, Mazdutide is positioning itself as a key player in the fight against obesity, potentially transforming treatment landscapes and improving quality of life for those affected.

As Innovent prepares for the regulatory submission, anticipation builds regarding the potential approval and subsequent availability of Mazdutide 9 mg for weight management. The success of the GLORY-2 trial inspires hope for more personalized and effective approaches to treating obesity in China, emphasizing the role of innovative biopharmaceuticals in enhancing population health.

About Innovent Biologics

Founded in 2011, Innovent is committed to delivering high-quality biopharmaceuticals and has successfully launched a variety of treatments across multiple therapeutic areas. With a collaborative approach that involves partnerships with global healthcare entities, Innovent focuses on advancing the biopharmaceutical industry and making significant strides in promoting healthier lives worldwide.